The Prognostic Significance of Micrometastases in Breast Cancer: a SEER Population-based Analysis
Overview
Affiliations
Introduction: The prognostic significance of lymph node micrometastases in breast cancer is controversial. We hypothesized that the survival of patients with solely micrometastatic disease (N1mi) would be intermediate to patients with 1-3 tumor-positive lymph nodes (N1) and those with no positive lymph nodes (N0).
Methods: We queried the surveillance, epidemiology and end results (SEER) database for all patients between 1992 and 2003 with invasive ductal or lobular breast cancer without distant metastases and < or = 3 axillary nodes with macroscopic disease. Patients were stratified by nodal involvement and compared using the Kaplan-Meier method. Cox proportional hazards regression was utilized to compare survival after adjusting for patient and tumor characteristics.
Results: Between 1992 and 2003, N1mi diagnoses increased from 2.3% to 7% among the 209,720 study patients (p < 0.001). In a T-stage stratified univariate analysis, N1mi patients had a worse prognosis in T2 lesions. On multivariate analysis, N1mi remained a significant prognostic indicator across all patients (p < 0.0001) with a hazard ratio of 1.35 compared to N0 disease and 0.82 compared to N1 disease. Other negative prognostic factors included male gender, estrogen-receptor negativity, progesterone-receptor negativity, lobular histology, higher grade, older age, higher T-stage, and diagnosis in an earlier time period.
Conclusion: Nodal micrometastasis of breast cancer carries a prognosis intermediate to N0 and N1 disease, even after adjusting for tumor- and patient-related factors. Prospective study is warranted and the results of pending trials are highly anticipated. Until then adjuvant therapy trials should consider using N1mi as a stratification factor when determining nodal status.
Teng L, Du J, Yan S, Xu P, Liu J, Zhao X Breast Cancer. 2024; 31(5):769-786.
PMID: 38802681 PMC: 11341746. DOI: 10.1007/s12282-024-01591-5.
Houvenaeghel G, Cohen M, Martino M, Reyal F, Classe J, Chauvet M Cancers (Basel). 2023; 15(18).
PMID: 37760536 PMC: 10526175. DOI: 10.3390/cancers15184567.
Luo S, Fu W, Lin J, Zhang J, Song C World J Surg Oncol. 2023; 21(1):202.
PMID: 37430331 PMC: 10332040. DOI: 10.1186/s12957-023-03082-x.
Fang W, Huang Y, Han X, Peng J, Zheng M Cancer Med. 2021; 11(3):764-777.
PMID: 34898007 PMC: 8817100. DOI: 10.1002/cam4.4469.
Houvenaeghel G, de Nonneville A, Cohen M, Chopin N, Coutant C, Reyal F ESMO Open. 2021; 6(3):100151.
PMID: 33984674 PMC: 8314870. DOI: 10.1016/j.esmoop.2021.100151.